HC Wainwright Has Positive Estimate for Clene Q2 Earnings

Clene Inc. (NASDAQ:CLNN) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings estimates for Clene in a research report issued to clients and investors on Thursday, May 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.35) per share for the quarter, up from their previous forecast of ($0.48). HC Wainwright currently has a “Buy” rating and a $31.00 target price on the stock. The consensus estimate for Clene’s current full-year earnings is ($1.99) per share. HC Wainwright also issued estimates for Clene’s Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($0.95) EPS and FY2028 earnings at ($0.62) EPS.

Several other research firms have also recently weighed in on CLNN. Canaccord Genuity Group reiterated a “buy” rating and set a $48.00 price objective on shares of Clene in a research report on Friday, March 13th. D. Boral Capital reiterated a “buy” rating and set a $23.00 price objective on shares of Clene in a research report on Monday, May 4th. Roth Mkm reiterated a “buy” rating on shares of Clene in a research report on Thursday. Finally, Weiss Ratings upgraded shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

Clene Stock Down 4.9%

CLNN opened at $6.79 on Tuesday. Clene has a twelve month low of $2.28 and a twelve month high of $13.50. The company has a fifty day moving average of $6.04 and a 200-day moving average of $6.36. The stock has a market cap of $86.78 million, a PE ratio of -2.12 and a beta of 0.89.

Clene (NASDAQ:CLNN) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.05). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million.

Institutional Investors Weigh In On Clene

Large investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp acquired a new stake in Clene in the third quarter worth $29,000. Jane Street Group LLC acquired a new stake in Clene in the second quarter worth $47,000. State Street Corp grew its holdings in Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after purchasing an additional 17,300 shares during the period. PEAK6 LLC acquired a new stake in Clene in the fourth quarter worth $294,000. Finally, Lunt Capital Management Inc. grew its holdings in Clene by 2.5% in the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after purchasing an additional 1,250 shares during the period. 23.28% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Clene news, major shareholder Chidozie Ugwumba sold 73,296 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $6.20, for a total value of $454,435.20. Following the completion of the sale, the insider directly owned 103,417 shares in the company, valued at approximately $641,185.40. This trade represents a 41.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 327,677 shares of company stock valued at $2,043,481 in the last ninety days. Company insiders own 28.30% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).